<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Hoth Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/hoth-therapeutics-inc</link>
<description>Latest news and press releases for Hoth Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 14 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/hoth-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68357f1978dffbe2df0fade9.webp</url>
<title>Hoth Therapeutics Inc</title>
<link>https://6ix.com/company/hoth-therapeutics-inc</link>
</image>
<item>
<title>Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide</title>
<link>https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-hoth-reports-positive-ht-va-crada-data-gdnf-reprograms-liver-fat-metabolism-shuts-down-fat-creation-gene-and-activates-fat-burning-pathways-outperforming-semaglutide</link>
<guid isPermaLink="true">https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-hoth-reports-positive-ht-va-crada-data-gdnf-reprograms-liver-fat-metabolism-shuts-down-fat-creation-gene-and-activates-fat-burning-pathways-outperforming-semaglutide</guid>
<pubDate>Tue, 14 Apr 2026 11:00:00 GMT</pubDate>
<description>Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced positive data from its HT-VA study, conducted under its Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Veterans Affairs and Emory University, demonstrating that parenteral GDNF (Glial Cell-Derived Neurotrophic Factor) directly reprograms liver fat metabolism at the genetic level in a preclinical model of metabolic-associated fatty liver disease (MAFLD).</description>
</item>
<item>
<title>Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering</title>
<link>https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-announces-closing-of-dollar20-million-registered-direct-offering</link>
<guid isPermaLink="true">https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-announces-closing-of-dollar20-million-registered-direct-offering</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>NEW YORK, April 2, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative</description>
</item>
<item>
<title>Hoth Therapeutics Announces $2.0 Million Registered Direct Offering</title>
<link>https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-announces-dollar20-million-registered-direct-offering-5</link>
<guid isPermaLink="true">https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-announces-dollar20-million-registered-direct-offering-5</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>NEW YORK, April 1, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative</description>
</item>
<item>
<title>Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology</title>
<link>https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-announces-issuance-of-chinese-patent-for-cancer-cell-targeting-technology</link>
<guid isPermaLink="true">https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-announces-issuance-of-chinese-patent-for-cancer-cell-targeting-technology</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>Technology Selectively Shuts Down Cancer Reproducing CellsPatent Covers Splice-Switching Oligonucleotide Platform Designed to Induce Apoptosis of Mast</description>
</item>
<item>
<title>Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery</title>
<link>https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-deploys-openclawtm-ai-platform-to-accelerate-drug-discovery</link>
<guid isPermaLink="true">https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-deploys-openclawtm-ai-platform-to-accelerate-drug-discovery</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>NEW YORK, March 26, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced the deployment of</description>
</item>
<item>
<title>Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption</title>
<link>https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-reports-positive-ht-001-pk-safety-and-clinical-activity-data-in-cancer-patients-with-egfr-therapy-associated-skin-toxicities-showing-77percent-increase-in-drug-exposure-and-minimal-systemic-absorption</link>
<guid isPermaLink="true">https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-reports-positive-ht-001-pk-safety-and-clinical-activity-data-in-cancer-patients-with-egfr-therapy-associated-skin-toxicities-showing-77percent-increase-in-drug-exposure-and-minimal-systemic-absorption</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>PK studies of topical HT-001 reveal limited systemic absorption and ~99% reduced systemic levels as compared to FDA approved oral formulations.Safety and</description>
</item>
<item>
<title>Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model</title>
<link>https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-reports-positive-female-preclinical-data-showing-ht-va-restores-cholesterol-levels-and-improves-lipid-metabolism-in-masld-model-1</link>
<guid isPermaLink="true">https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-reports-positive-female-preclinical-data-showing-ht-va-restores-cholesterol-levels-and-improves-lipid-metabolism-in-masld-model-1</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>HT-VA restores cholesterol to control-diet levels and maintains lower triglycerides compared with semaglutide in western diet–fed female miceTreatment</description>
</item>
<item>
<title>Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program</title>
<link>https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-deploys-openai-api-to-advance-development-of-orphan-ht-kit-oncology-program</link>
<guid isPermaLink="true">https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-deploys-openai-api-to-advance-development-of-orphan-ht-kit-oncology-program</guid>
<pubDate>Wed, 04 Mar 2026 13:31:00 GMT</pubDate>
<description>Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company advancing breakthrough therapies for diseases, today announced the deployment of the OpenAI API to support IND-enabling development of HT-KIT, its orphan-designated therapy targeting rare and aggressive KIT-driven cancers.</description>
</item>
<item>
<title>HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES</title>
<link>https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-accelerates-ht-001-trial-enrollment-with-new-clinical-site-as-patient-demand-increases</link>
<guid isPermaLink="true">https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-accelerates-ht-001-trial-enrollment-with-new-clinical-site-as-patient-demand-increases</guid>
<pubDate>Tue, 24 Feb 2026 21:15:00 GMT</pubDate>
<description>Hoth Therapeutics, Inc. (NASDAQ: HOTH) today announced a significant expansion of its CLEER-001 Phase 2a clinical trial with the addition of Regis Clinical Research as a new enrolling site. Located in Miami, Florida, Regis joins the growing CLEER-001 investigational site network as surging patient demand outpaces capacity at existing sites — a direct reflection of the compelling early clinical results HT-001 has produced and the desperate unmet need it addresses.</description>
</item>
<item>
<title>Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases</title>
<link>https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-receives-u-notice-133300311</link>
<guid isPermaLink="true">https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-receives-u-notice-133300311</guid>
<pubDate>Thu, 12 Feb 2026 13:33:00 GMT</pubDate>
<description>Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company advancing breakthrough therapies for diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for "Exon Skipping of FC-Epsilon-RI-Beta and MS4A6A in the Treatment of Allergic Diseases."</description>
</item>
<item>
<title>Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model</title>
<link>https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-announces-groundbreaking-positive-133000691</link>
<guid isPermaLink="true">https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-announces-groundbreaking-positive-133000691</guid>
<pubDate>Tue, 10 Feb 2026 13:30:00 GMT</pubDate>
<description>Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company developing innovative therapies for unmet medical needs, today announced compelling preclinical data from its VA-backed study on glial cell-derived neurotrophic factor (GDNF) as a novel treatment for obesity and metabolic-associated steatotic liver disease (MASLD). In a head-to-head comparison, GDNF demonstrated superior efficacy over semaglutide (the active ingredient in Wegovy® and Ozempic®) in key metrics, inc</description>
</item>
<item>
<title>Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets</title>
<link>https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-addresses-market-rumor-130300339</link>
<guid isPermaLink="true">https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-addresses-market-rumor-130300339</guid>
<pubDate>Thu, 05 Feb 2026 13:03:00 GMT</pubDate>
<description>Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on advancing innovative therapies for cancer patients with significant unmet needs, today announced over the last several days investors have contacted the company re our exposure to digital assets such as Bitcoin , Solana and Ethereum. Hoth holds no cryptocurrency assets, and its maximum exposure never reached more than $350,000 USD over the last year. Hoth continues to execute on its HT-001 clinical tria</description>
</item>
<item>
<title>Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients</title>
<link>https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-delivers-100-clinical-131300735</link>
<guid isPermaLink="true">https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-delivers-100-clinical-131300735</guid>
<pubDate>Thu, 22 Jan 2026 13:13:00 GMT</pubDate>
<description>Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on advancing innovative therapies for cancer patients with significant unmet needs, today announced positive interim results from the open-label pharmacokinetic (PK) cohort of its ongoing CLEER-001 clinical trial evaluating HT-001 in cancer patients receiving EGFR inhibitor therapy.</description>
</item>
<item>
<title>Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position</title>
<link>https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-secures-major-international-131300020</link>
<guid isPermaLink="true">https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-secures-major-international-131300020</guid>
<pubDate>Wed, 21 Jan 2026 13:13:00 GMT</pubDate>
<description>Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapeutics, today announced that the China National Intellectual Property Administration has approved issuance of a key patent covering the Company's HT-KIT cancer program, a novel therapeutic approach designed to induce apoptosis in disease-driving cells by targeting KIT signaling pathways.</description>
</item>
<item>
<title>Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation</title>
<link>https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-reaches-key-eu-131700605</link>
<guid isPermaLink="true">https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-reaches-key-eu-131700605</guid>
<pubDate>Thu, 15 Jan 2026 13:17:00 GMT</pubDate>
<description>Hoth Therapeutics, Inc.(NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing therapies for serious and underserved conditions, today announced it has achieved a major European regulatory milestone for its HT-001 clinical program targeting cancer patients undergoing EGFR inhibitor therapies.</description>
</item>
<item>
<title>Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform</title>
<link>https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-expands-oncology-pipeline-131300139</link>
<guid isPermaLink="true">https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-expands-oncology-pipeline-131300139</guid>
<pubDate>Fri, 02 Jan 2026 13:13:00 GMT</pubDate>
<description>Hoth Therapeutics (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies for underserved medical needs, today announced the filing of two U.S. provisional patent applications that significantly expand the Company's intellectual property portfolio and establish a new oncology-focused dermatology platform targeting treatment-induced skin toxicity from modern cancer therapies.</description>
</item>
<item>
<title>Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program</title>
<link>https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-issues-comprehensive-pipeline-190000629</link>
<guid isPermaLink="true">https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-issues-comprehensive-pipeline-190000629</guid>
<pubDate>Wed, 03 Dec 2025 19:00:00 GMT</pubDate>
<description>Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today issued a comprehensive update on its therapeutic pipeline. The Company detailed meaningful progress across HT-001, HT-KIT, HT-ALZ, and its newly launched GDNF-based metabolic program, while continuing to strengthen its global intellectual-property portfolio and expand strategic research partnerships.</description>
</item>
<item>
<title>Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025</title>
<link>https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-present-noble-capital-130300498</link>
<guid isPermaLink="true">https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-present-noble-capital-130300498</guid>
<pubDate>Mon, 01 Dec 2025 13:03:00 GMT</pubDate>
<description>Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced that Robb Knie, Chief Executive Officer, is scheduled to present at the Noble Capital Markets 21st Annual Emerging Growth Equity Conference in Boca Raton, FL.</description>
</item>
<item>
<title>Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities</title>
<link>https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-accepted-nvidia-connect-131300397</link>
<guid isPermaLink="true">https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-accepted-nvidia-connect-131300397</guid>
<pubDate>Thu, 20 Nov 2025 13:13:00 GMT</pubDate>
<description>Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing breakthrough therapeutics today announced that it has been officially accepted into the NVIDIA Connect Program, a global initiative supporting innovative software and technology companies working with advanced computing and AI platforms.</description>
</item>
<item>
<title>Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease</title>
<link>https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-launches-va-backed-114900593</link>
<guid isPermaLink="true">https://6ix.com/company/hoth-therapeutics-inc/news/hoth-therapeutics-launches-va-backed-114900593</guid>
<pubDate>Mon, 27 Oct 2025 11:49:00 GMT</pubDate>
<description>Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing breakthrough therapies for metabolic, dermatologic, and inflammatory diseases, today announced the initiation of a U.S. Department of Veterans Affairs (VA)–backed study evaluating the potential of glial cell line–derived neurotrophic factor (GDNF)as a novel therapy for obesity and fatty liver disease (hepatic steatosis).</description>
</item>
</channel>
</rss>